拉贝洛尔联合硫酸镁治疗重度妊娠期高血压疾病的效果分析
|
摘要
目的:探讨重度妊娠期高血压疾病患者实施拉贝洛尔联合硫酸镁治疗的临床效果。方法:选择本院2015年1月-2017年1月收治的70例重度妊娠期高血压疾病患者实施观察研究,按患者治疗方案实施分组,分为常规组(n=35)和联合组(n=35)。常规组实施硫酸镁治疗,联合组实施拉贝洛尔联合硫酸镁治疗,对比分析不同治疗方案患者的治疗效果、临床表现、母婴结局、用药不良反应发生情况。结果:联合组患者的治疗总有效率为94.3%,高于常规组的77.1%,差异有统计学意义(X~2=4.200,P=0.040);联合组患者治疗后收缩压为(135.2±9.5)mm Hg、舒张压为(85.6±6.2)mm Hg、24 h蛋白尿水平为(1.8±0.6)g,均低于常规组的收缩压(146.5±10.7)mm Hg、舒张压(96.5±6.7)mm Hg、24 h蛋白尿水平(2.4±0.7)g,差异均有统计学意义(P<0.05);联合组患者子痫、产后出血、胎盘早剥、胎儿窘迫、新生儿窒息、低体重儿发生率分别为2.9%、8.6%、0、2.9%、5.7%、5.7%,均低于常规组患者的20.0%、34.3%、17.1%、20.0%、25.7%、22.9%,差异均有统计学意义(P<0.05)。联合组患者用药不良反应发生率为11.4%,与常规组的17.1%比较,差异无统计学意义(X~2=0.467,P=0.495)。结论:重度妊娠期高血压疾病患者实施拉贝洛尔联合硫酸镁治疗的临床效果显著,可改善母婴预后。
Objective:To investigate the clinical effect of Labetalol combined with Magnesium Sulfate in patients with severe hypertensive disorder complicating pregnancy.Method:70 patients with severe hypertensive disorder complicating pregnancy in our hospital from January 2015 to January 2017 were selected to carry out an observation study,according to the treatment plan of patients,they were divided into routine group(n=35)and combination group(n=35).The routine group was given Magnesium Sulfate,the combination group was treated with Labetalol combined with Magnesium Sulfate.The treatment effect,clinical manifestations,maternal and infant outcomes and the adverse drug reactions of the patients under different treatment regimens were compared and analyzed.Result:The total effective rate of the combination group was 94.3%,which was higher than 77.1% of the routine group,the difference was statistically significant( X~2=4.200,P=0.040);after treatment,systolic blood pressure was(135.2±9.5)mm Hg,diastolic was(85.6±6.2)mm Hg,and 24 h proteinuria level was(1.8±0.6)g in the combination group,which were lower than(146.5±10.7)mm Hg,(96.5±6.7)mm Hg and(2.4±0.7)g of the control group,the differences were statistically significant(P<0.05).The incidences of eclampsia,postpartum hemorrhage,placental abruption,fetal distress,neonatal asphyxia and low birth weight in the combination group were 2.9%,8.6%,0,2.9%,5.7%,5.7% respectively,which were significantly lower than 20.0%,34.3%,17.1%,20.0%,25.7%,22.9% in the routine group,the differences were statistically significant(P<0.05).The incidence of adverse drug reactions in the combined group was 11.4%,compared with 17.1% in the routine group,the difference was not statistically significant( X~2=0.467,P=0.495).Conclusion:The clinical effect of Labetalol combined with Magnesium Sulfate in patients with severe hypertensive disorder complicating pregnancy is significant,which can improve the prognosis of maternal and infant.
Objective:To investigate the clinical effect of Labetalol combined with Magnesium Sulfate in patients with severe hypertensive disorder complicating pregnancy.Method:70 patients with severe hypertensive disorder complicating pregnancy in our hospital from January 2015 to January 2017 were selected to carry out an observation study,according to the treatment plan of patients,they were divided into routine group(n=35)and combination group(n=35).The routine group was given Magnesium Sulfate,the combination group was treated with Labetalol combined with Magnesium Sulfate.The treatment effect,clinical manifestations,maternal and infant outcomes and the adverse drug reactions of the patients under different treatment regimens were compared and analyzed.Result:The total effective rate of the combination group was 94.3%,which was higher than 77.1% of the routine group,the difference was statistically significant( X~2=4.200,P=0.040);after treatment,systolic blood pressure was(135.2±9.5)mm Hg,diastolic was(85.6±6.2)mm Hg,and 24 h proteinuria level was(1.8±0.6)g in the combination group,which were lower than(146.5±10.7)mm Hg,(96.5±6.7)mm Hg and(2.4±0.7)g of the control group,the differences were statistically significant(P<0.05).The incidences of eclampsia,postpartum hemorrhage,placental abruption,fetal distress,neonatal asphyxia and low birth weight in the combination group were 2.9%,8.6%,0,2.9%,5.7%,5.7% respectively,which were significantly lower than 20.0%,34.3%,17.1%,20.0%,25.7%,22.9% in the routine group,the differences were statistically significant(P<0.05).The incidence of adverse drug reactions in the combined group was 11.4%,compared with 17.1% in the routine group,the difference was not statistically significant( X~2=0.467,P=0.495).Conclusion:The clinical effect of Labetalol combined with Magnesium Sulfate in patients with severe hypertensive disorder complicating pregnancy is significant,which can improve the prognosis of maternal and infant.
引文
[1]戴薇,许吟,马星卫,等.小剂量低分子肝素联合硫酸镁治疗重度子痫前期对血清和胎盘中病情相关分子的调节作用[J].中国现代医学杂志,2016,26(18):30-33.
[2]张晨凌.黄芪注射液联合盐酸拉贝洛尔和硫酸镁治疗妊娠高血压综合征的临床研究[J].现代药物与临床,2016,31(3):324-328.
[3]韩秋玥,马海英,王晓帆,等.硫酸镁联合拉贝洛尔对妊娠高血压患者血清丙二醛和谷胱甘肽过氧化酶及血浆总抗氧化能力与超氧化物歧化酶的影响[J].中国医药,2017,12(4):589-592.
[4]胡冬冬.硫酸镁联合拉贝洛尔硝苯地平治疗重度子痫前期72例临床疗效观察[J].中国药物与临床,2016,16(2):277-279.
[5]符泽美,王爱丽,裴雄越,等.硫酸镁联合硝苯地平或拉贝洛尔治疗妊娠高血压疗效比较[J].海南医学,2016,27(14):2346-2348.
[6]隋珍,邵彩华.复方丹参注射液联合硫酸镁治疗妊娠期高血压疾病的疗效及对血清ET-1、NO、Hcy和v WF水平的影响[J].中国妇幼保健,2017,32(17):4055-4058.
[7]喻云倩,张媛,李隆华,等.硫酸镁联合拉贝洛尔与硫酸镁联合尼莫地平治疗子痫前期的疗效比较[J].实用临床医药杂志,2017,21(3):173-174.
[8]王琴娟,徐英.甲基多巴联合拉贝洛尔治疗妊娠期高血压疾病的疗效及安全性分析[J].中国妇幼保健,2017,32(1):23-25.
[9]李介岩,王欣,张为远,等.硫酸镁对妊娠期高血压血清中血管内皮生长因子和肿瘤坏死因子-α影响的实验研究[J].中国临床医生杂志,2016,44(7):91-93.
[10]王晓临,肖建平.硫酸镁联合拉贝洛尔治疗早发型重度子痫前期效果观察[J].山东医药,2016,56(44):63-64.
[11]谢桂英,马玉燕.拉贝洛尔对中重度妊娠期高血压疾病患者心肾功能及妊娠结局的影响及机制[J].山东医药,2017,57(21):74-76.
[12]李广隽,刘晓巍,武绍文,等.硫酸镁联合硝苯地平治疗中重度妊娠高血压综合征患者的疗效观察[J].现代生物医学进展,2015,15(25):4896-4898,4933.
[13]赵清.硫酸镁与硝苯地平联合对中重度妊娠期高血压疾病患者的有效性评价[J].中国妇幼保健,2016,31(5):1084-1085.
[14]董完秀.硝苯地平联合硫酸镁对妊娠高血压的治疗效果分析[J].山西医药杂志,2016,45(23):2774-2777.
[15]季献微,周玲玲,钟晓芳,等.硝苯地平联合硫酸镁治疗妊娠高血压的疗效观察[J].中国社区医师,2017,33(14):81,83.
[16]宋娟利.复方丹参注射液联合硫酸镁治疗妊娠期高血压疾病及对患者微炎症状态、肾功能的影响[J].陕西中医,2016,37(4):406-407.
[17]许曼,李丽贤,廖义鸿,等.甲基多巴及拉贝洛尔联合硫酸镁对重度早发型子痫前期患者的疗效及安全性分析[J].中国生育健康杂志,2017,28(3):237-239.
[18]温洁红,胡蕾.硫酸镁联合硝苯地平及拉贝洛尔治疗子痫前期高血压的临床观察[J].岭南心血管病杂志,2015,21(4):537-538.
[19]李俊菲,邹明英.拉贝洛尔对妊娠高血压患者血压临床效果及分娩结局的影响[J].实用预防医学,2015,22(4):487-489.
[20]阮琦,区淑珍.甲基多巴联合拉贝洛尔治疗妊娠高血压的疗效观察及其机制探讨[J].岭南心血管病杂志,2016,22(4):446-448,459.
[21]王亚军.拉贝洛尔联合硫酸镁治疗妊娠高血压疾病的临床效果观察及不良反应评价[J].河北医科大学学报,2016,37(10):1211-1214.
[22]管正秀.硫酸镁和拉贝洛尔联合治疗早发型重度子痫前期的效果观察[J].中国医药导刊,2016,18(1):85-86.
[2]张晨凌.黄芪注射液联合盐酸拉贝洛尔和硫酸镁治疗妊娠高血压综合征的临床研究[J].现代药物与临床,2016,31(3):324-328.
[3]韩秋玥,马海英,王晓帆,等.硫酸镁联合拉贝洛尔对妊娠高血压患者血清丙二醛和谷胱甘肽过氧化酶及血浆总抗氧化能力与超氧化物歧化酶的影响[J].中国医药,2017,12(4):589-592.
[4]胡冬冬.硫酸镁联合拉贝洛尔硝苯地平治疗重度子痫前期72例临床疗效观察[J].中国药物与临床,2016,16(2):277-279.
[5]符泽美,王爱丽,裴雄越,等.硫酸镁联合硝苯地平或拉贝洛尔治疗妊娠高血压疗效比较[J].海南医学,2016,27(14):2346-2348.
[6]隋珍,邵彩华.复方丹参注射液联合硫酸镁治疗妊娠期高血压疾病的疗效及对血清ET-1、NO、Hcy和v WF水平的影响[J].中国妇幼保健,2017,32(17):4055-4058.
[7]喻云倩,张媛,李隆华,等.硫酸镁联合拉贝洛尔与硫酸镁联合尼莫地平治疗子痫前期的疗效比较[J].实用临床医药杂志,2017,21(3):173-174.
[8]王琴娟,徐英.甲基多巴联合拉贝洛尔治疗妊娠期高血压疾病的疗效及安全性分析[J].中国妇幼保健,2017,32(1):23-25.
[9]李介岩,王欣,张为远,等.硫酸镁对妊娠期高血压血清中血管内皮生长因子和肿瘤坏死因子-α影响的实验研究[J].中国临床医生杂志,2016,44(7):91-93.
[10]王晓临,肖建平.硫酸镁联合拉贝洛尔治疗早发型重度子痫前期效果观察[J].山东医药,2016,56(44):63-64.
[11]谢桂英,马玉燕.拉贝洛尔对中重度妊娠期高血压疾病患者心肾功能及妊娠结局的影响及机制[J].山东医药,2017,57(21):74-76.
[12]李广隽,刘晓巍,武绍文,等.硫酸镁联合硝苯地平治疗中重度妊娠高血压综合征患者的疗效观察[J].现代生物医学进展,2015,15(25):4896-4898,4933.
[13]赵清.硫酸镁与硝苯地平联合对中重度妊娠期高血压疾病患者的有效性评价[J].中国妇幼保健,2016,31(5):1084-1085.
[14]董完秀.硝苯地平联合硫酸镁对妊娠高血压的治疗效果分析[J].山西医药杂志,2016,45(23):2774-2777.
[15]季献微,周玲玲,钟晓芳,等.硝苯地平联合硫酸镁治疗妊娠高血压的疗效观察[J].中国社区医师,2017,33(14):81,83.
[16]宋娟利.复方丹参注射液联合硫酸镁治疗妊娠期高血压疾病及对患者微炎症状态、肾功能的影响[J].陕西中医,2016,37(4):406-407.
[17]许曼,李丽贤,廖义鸿,等.甲基多巴及拉贝洛尔联合硫酸镁对重度早发型子痫前期患者的疗效及安全性分析[J].中国生育健康杂志,2017,28(3):237-239.
[18]温洁红,胡蕾.硫酸镁联合硝苯地平及拉贝洛尔治疗子痫前期高血压的临床观察[J].岭南心血管病杂志,2015,21(4):537-538.
[19]李俊菲,邹明英.拉贝洛尔对妊娠高血压患者血压临床效果及分娩结局的影响[J].实用预防医学,2015,22(4):487-489.
[20]阮琦,区淑珍.甲基多巴联合拉贝洛尔治疗妊娠高血压的疗效观察及其机制探讨[J].岭南心血管病杂志,2016,22(4):446-448,459.
[21]王亚军.拉贝洛尔联合硫酸镁治疗妊娠高血压疾病的临床效果观察及不良反应评价[J].河北医科大学学报,2016,37(10):1211-1214.
[22]管正秀.硫酸镁和拉贝洛尔联合治疗早发型重度子痫前期的效果观察[J].中国医药导刊,2016,18(1):85-86.